<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04982588</url>
  </required_header>
  <id_info>
    <org_study_id>MDT18065EVR009</org_study_id>
    <nct_id>NCT04982588</nct_id>
  </id_info>
  <brief_title>Evolut PRO China Clinical Study</brief_title>
  <official_title>Medtronic CoreValve™ Evolut™ PRO System China Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiovascular</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional study to evaluate the safety and efficacy of the Medtronic CoreValve™ Evolut™&#xD;
      PRO System when used by China implanting centers in Chinese patients with severe symptomatic&#xD;
      aortic stenosis (AS) who are at high risk for Surgical Aortic Valve Replacement (SAVR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, single arm, multi-center, interventional, pre-market trial to&#xD;
      obtain clinical data from Chinese implanting centers to support product registration of the&#xD;
      Medtronic CoreValve™ Evolut™ PRO System (TAV, DCS and LS) with the National Medical Product&#xD;
      Administration (NMPA) in China. Estimating 65 subjects with a maximum of up to 70 subjects in&#xD;
      China with an attempted implant and followed the assessment with pre and post-procedure,&#xD;
      discharge, 30 days(primary endpoint), 6months, 1 year, and annually through 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of participants with all-cause mortality, cardiovascular and non-cardiovascular mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage (%) of evaluable echocardiograms with moderate or severe aortic regurgitation</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage (%) of evaluable echocardiograms with moderate or severe aortic regurgitation by transthoracic echocardiography (TTE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of an VARC II combined composite</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of an VARC II combined composite includes the following components:&#xD;
All-cause mortality&#xD;
All stroke (disabling and non-disabling)&#xD;
Life-threatening bleeding&#xD;
Acute kidney injury: stage 2 or 3 (including renal replacement therapy)&#xD;
Coronary artery obstruction requiring intervention&#xD;
Major vascular complication&#xD;
Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event rates of the individual components of the VARC II composite</measure>
    <time_frame>30 days</time_frame>
    <description>Event rate of the individual components listed in the outcome 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New permanent pacemaker rate</measure>
    <time_frame>30 days</time_frame>
    <description>New permanent pacemaker rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success rate</measure>
    <time_frame>Between 24 hours and 7 days post procedure</time_frame>
    <description>Device success rate:&#xD;
Percentage of participants with absence of procedural mortality, AND&#xD;
Percentage of participants with correct positioning of a single prosthetic heart valve into the proper anatomical location, AND&#xD;
Percentage of participants with intended performance of the prosthetic heart valve, defined as the absence of patient-prosthesis-mismatch and mean aortic valve gradient less than 20 mmHg (or peak velocity &lt;3m/sec), AND absence of moderate or severe prosthetic valve regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve performance parameter - Mean aortic gradient</measure>
    <time_frame>30 days</time_frame>
    <description>• Mean aortic gradient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve performance parameter - Effective orifice area</measure>
    <time_frame>30 days</time_frame>
    <description>• Effective orifice area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve performance parameter -Degree of aortic regurgitation (transvalvular, paravalvular, total)</measure>
    <time_frame>30 days</time_frame>
    <description>• Degree of aortic regurgitation (transvalvular, paravalvular, total)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Event rates of TAVI-related complications</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Rate of the following TAVI-related complications:&#xD;
change to surgery&#xD;
need for cardiopulmonary mechanical assistance&#xD;
coronary occlusion or obstruction&#xD;
annular rupture or dissection&#xD;
ventricular perforation&#xD;
mitral valve damage&#xD;
prosthetic valve displacement, migration, or embolism&#xD;
acute kidney injury (up to 7 days post procedure)</description>
  </other_outcome>
  <other_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Percentage of participants with all-cause mortality, cardiovascular and non-cardiovascular mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>All stroke</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of stroke (disabling and non-disabling)</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>30days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of periprocedural MI and spontaneous MI</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of life-threatening bleeding</measure>
    <time_frame>30days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of life-threatening bleeding:&#xD;
Fatal bleeding (BARC type 5) OR&#xD;
Bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR&#xD;
Bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR&#xD;
Overt source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* (BARC type 3b)</description>
  </other_outcome>
  <other_outcome>
    <measure>New AV-Conduction disturbances</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of left bundle branch block and Right bundle branch block</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of prosthetic valve endocarditis</measure>
    <time_frame>30days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of prosthetic valve endocarditis:&#xD;
Fulfillment of the following Duke criteria for definite endocarditis&#xD;
Evidence of abscess, paravalvular leak, pus, or vegetation confirmed as secondary to infection by histological or bacteriological studies during a re-operation&#xD;
Findings of abscess, pus, or vegetation involving the CoreValve™ Evolut™ PRO at autopsy</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Prosthetic valve thrombosis</measure>
    <time_frame>30days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of Prosthetic valve thrombosis:&#xD;
Any thrombus attached to or near an implanted valve that occludes part of the blood flow path, interferes with valve function, or is sufficiently large to warrant treatment.&#xD;
*Valve-associated thrombus identified at autopsy in a patient whose cause of death was not valve related should not be reported as valve thrombosis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of valve-related dysfunction</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of valve-related dysfunction defined as moderate or severe prosthetic valve stenosis, or moderate or severe prosthetic regurgitation (per VARC II)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Valve-related dysfunction requiring repeat procedure</measure>
    <time_frame>30days, 6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of Valve-related dysfunction requiring repeat procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Valve hemodynamic performance metric - Mean aortic gradient</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>• Mean aortic gradient</description>
  </other_outcome>
  <other_outcome>
    <measure>Valve hemodynamic performance metric - Effective orifice area</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>• Effective orifice area</description>
  </other_outcome>
  <other_outcome>
    <measure>Valve hemodynamic performance metric - Degree of aortic regurgitation (transvalvular, paravalvular, total)</measure>
    <time_frame>1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>• Degree of aortic regurgitation (transvalvular, paravalvular, total)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of New York Heart Association (NYHA) functional classification</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years and 5 years</time_frame>
    <description>Incidence of New York Heart Association (NYHA) functional classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life change from baseline EuroQol-5 Dimension [EQ-5D]</measure>
    <time_frame>30 days, 1 year</time_frame>
    <description>QoL: EQ-5D</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Severe, Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Medtronic CoreValve™ Evolut™ PRO System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The system comprised of the following three components:&#xD;
CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)&#xD;
EnVeo™ PRO Delivery Catheter System (DCS)&#xD;
EnVeo™ PRO Loading System (LS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve™ Evolut™ PRO System</intervention_name>
    <description>The system comprised of the following three components:&#xD;
CoreValve™ Evolut™ PRO Transcatheter Aortic Valve (TAV)&#xD;
EnVeo™ PRO Delivery Catheter System (DCS)&#xD;
EnVeo™ PRO Loading System (LS)</description>
    <arm_group_label>Medtronic CoreValve™ Evolut™ PRO System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aortic valve area (AVA) &lt; 1.0 cm2 (or indexed AVA &lt;0.6 cm2/m2) OR mean gradient &gt; 40&#xD;
             mmHg, OR max aortic velocity &gt; 4.0 m/sec&#xD;
&#xD;
          2. High risk for SAVR defined as STS-PROM score ≥ 8% AND ≤ 15%, OR documented Heart Team&#xD;
             agreement of high risk for AVR due to frailty or comorbidities&#xD;
&#xD;
          3. Symptoms of aortic stenosis and NYHA ≥ II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age is less than 65 years old&#xD;
&#xD;
          2. Non-calcified aortic valve&#xD;
&#xD;
          3. Bicuspid aortic valve with no raphe or 2 raphes (Sievers classification type 0 or type&#xD;
             2)&#xD;
&#xD;
          4. Ascending aortic diameter &gt; 4.5 cm&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianan Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yolanda Wang</last_name>
    <phone>+86-10-5322 7124</phone>
    <email>yolanda.wang2@medtronic.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian'an WANG, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

